Mirum Advances Rare Disease Pipeline | Business and Finance News

Mirum Pharmaceuticals is on a roll, reporting strong Q2 sales of $176 million and bumping up its full-year forecast to $680–700 million. Their FOP drug Zilurgisertib is poised for approval next month with a Q4 launch. For rare liver diseases, volixibat for PSC hit its key goal and earned breakthrough status, though FDA discussions pushed its submission to early next year. The VANTAGE study for PBC is enrolling and expected to deliver results soon. Financially, Mirum’s cash reserves hit over $560 million, bolstered by $670 million from convertible notes, giving them flexibility to fund growth. The pipeline is packed: more volixibat/volovitug data this year, potential new drug apps next year, and early fragile X data on the horizon. Despite a slight delay in PSC submission, Mirum’s momentum is clear — they’re building a powerhouse in rare disease treatments while staying financially agile. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/8cee2f1be38cd395